Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication.

ABSTRACT: Since 2015, 69 countries and territories have reported evidence of vector-borne Zika virus (ZIKV) transmission. Currently, there are no effective licensed vaccines or drugs available for the treatment or prevention of ZIKV infection. We tested a series of compounds for their ability to inhibit ZIKV replication in cell culture. The compounds in T-705 (favipiravir) and T-1105 were found to have antiviral activity, suggesting that these compounds are promising candidates for further development as specific antiviral drugs against ZIKV.

SUBMITTER: Cai L 

PROVIDER: S-EPMC5563514 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature